JP2019535232A5 - - Google Patents

Download PDF

Info

Publication number
JP2019535232A5
JP2019535232A5 JP2019502698A JP2019502698A JP2019535232A5 JP 2019535232 A5 JP2019535232 A5 JP 2019535232A5 JP 2019502698 A JP2019502698 A JP 2019502698A JP 2019502698 A JP2019502698 A JP 2019502698A JP 2019535232 A5 JP2019535232 A5 JP 2019535232A5
Authority
JP
Japan
Prior art keywords
antibody
seq
antigen
binding portion
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019502698A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019535232A (ja
JP7039554B2 (ja
Filing date
Publication date
Priority claimed from GBGB1614162.4A external-priority patent/GB201614162D0/en
Application filed filed Critical
Publication of JP2019535232A publication Critical patent/JP2019535232A/ja
Publication of JP2019535232A5 publication Critical patent/JP2019535232A5/ja
Priority to JP2022035222A priority Critical patent/JP7486538B2/ja
Application granted granted Critical
Publication of JP7039554B2 publication Critical patent/JP7039554B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019502698A 2016-08-18 2017-08-18 抗psma抗体、その使用及びそのコンジュゲート Active JP7039554B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022035222A JP7486538B2 (ja) 2016-08-18 2022-03-08 抗psma抗体、その使用及びそのコンジュゲート

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1614162.4A GB201614162D0 (en) 2016-08-18 2016-08-18 Antibodies, uses thereof and conjugates thereof
GB1614162.4 2016-08-18
PCT/GB2017/052448 WO2018033749A1 (en) 2016-08-18 2017-08-18 Anti-psma antibodies, uses thereof and conjugates thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022035222A Division JP7486538B2 (ja) 2016-08-18 2022-03-08 抗psma抗体、その使用及びそのコンジュゲート

Publications (3)

Publication Number Publication Date
JP2019535232A JP2019535232A (ja) 2019-12-12
JP2019535232A5 true JP2019535232A5 (OSRAM) 2020-09-17
JP7039554B2 JP7039554B2 (ja) 2022-03-22

Family

ID=57045541

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019502698A Active JP7039554B2 (ja) 2016-08-18 2017-08-18 抗psma抗体、その使用及びそのコンジュゲート
JP2022035222A Active JP7486538B2 (ja) 2016-08-18 2022-03-08 抗psma抗体、その使用及びそのコンジュゲート

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022035222A Active JP7486538B2 (ja) 2016-08-18 2022-03-08 抗psma抗体、その使用及びそのコンジュゲート

Country Status (7)

Country Link
US (1) US11059903B2 (OSRAM)
EP (2) EP3500595B1 (OSRAM)
JP (2) JP7039554B2 (OSRAM)
CN (1) CN110049999B (OSRAM)
ES (1) ES2983492T3 (OSRAM)
GB (1) GB201614162D0 (OSRAM)
WO (1) WO2018033749A1 (OSRAM)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018204477A1 (en) 2017-05-02 2018-11-08 Cornell University Methods and reagents for tumor targeting with greater efficacy and less toxicity
WO2019173324A1 (en) 2018-03-06 2019-09-12 The Trustees Of The University Of Pennsylvania Prostate-specific membrane antigen cars and methods of use thereof
WO2019191728A1 (en) * 2018-03-29 2019-10-03 Ambrx, Inc. Humanized anti-prostate-specific membrane antigen (psma) antibody drug conjugates
EP3994177A4 (en) * 2019-07-02 2023-09-20 Telix International Pty Ltd PSMA-BINDING ANTIBODIES WITH REDUCED AFFINITY FOR THE NEONATAL FC RECEPTOR
AU2020347171A1 (en) 2019-09-11 2022-03-10 The Trustees Of The University Of Pennsylvania Compositions and methods comprising prostate stem cell antigen (PSCA) chimeric antigen receptors (CARs)
WO2021098834A1 (zh) * 2019-11-22 2021-05-27 上海一宸医药科技有限公司 Psma抗体及其应用
CN110922486B (zh) * 2020-02-18 2020-05-22 和铂医药(上海)有限责任公司 一种分离的结合抗原psma的蛋白及其用途
WO2024182569A2 (en) * 2023-02-28 2024-09-06 Eisai R&D Management Co., Ltd. Anti-psma antibodies, conjugates, and methods of use
JP2026507228A (ja) 2023-03-03 2026-02-27 アーセナル バイオサイエンシズ インコーポレイテッド Psma及びca9を標的とするシステム
CN116196428B (zh) * 2023-04-04 2025-04-04 上海愿智生物技术有限公司 一种药物组合物及其应用
CN116271081A (zh) * 2023-04-04 2023-06-23 上海愿智生物技术有限公司 一种抗体偶联药物yc1605及其药物组合物和应用
WO2026044149A2 (en) 2024-08-21 2026-02-26 Eisai R&D Management Co., Ltd. Synthesis of drug-linker combinations for antibody-drug conjugates

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6107090A (en) 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
CN1294588C (zh) 1996-07-24 2007-01-10 皇家菲利浦电子有限公司 光盘录取装置
US7514078B2 (en) 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
US20050215472A1 (en) 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
EP2360169B1 (en) 2001-10-23 2015-10-14 Psma Development Company, L.L.C. PSMA antibodies
US20040136998A1 (en) 2002-10-30 2004-07-15 Bander Neil H. Methods and compositions for treating or preventing insulin-related disorders using binding agents specific for prostate specific membrane antigen
GB0314472D0 (en) 2003-06-20 2003-07-23 Warwick Effect Polymers Ltd Polymer
GB0316294D0 (en) 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
MX2007009878A (es) 2005-02-18 2007-10-03 Medarex Inc Anticuerpos monoclonales para antigeno de membrana especifica para prostata (amep).
CN101160324B (zh) * 2005-02-18 2013-04-24 米德列斯公司 缺乏岩藻糖残基的抗前列腺特异性膜抗原(psma)单克隆抗体
WO2009017823A2 (en) * 2007-08-01 2009-02-05 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health Of Human Services, National Institutes Of Health A fold-back diabody diphtheria toxin immunotoxin and methods of use
DK2209494T3 (en) 2007-10-09 2016-10-03 Polytherics Ltd New conjugated proteins and peptides
CN101891818B (zh) * 2009-01-16 2012-07-25 中国人民解放军第四军医大学 抗人前列腺特异性膜抗原胞外区单链抗体及其应用
US9005598B2 (en) 2009-03-04 2015-04-14 Polytherics Limited Conjugated proteins and peptides
SG11201407600UA (en) * 2012-06-19 2014-12-30 Polytherics Ltd Novel process for preparation of antibody conjugates and novel antibody conjugates
US20150290342A1 (en) * 2012-10-24 2015-10-15 Polytherics Limited Drug-protein conjugates
NO2789793T3 (OSRAM) 2012-10-24 2018-01-27
JP6857028B2 (ja) * 2013-03-15 2021-04-14 メモリアル スローン ケタリング キャンサー センター 免疫治療のための組成物および方法
JP6908964B2 (ja) * 2013-10-18 2021-07-28 ピーエスエムエー ディベロップメント カンパニー,エルエルシー Psmaリガンドコンジュゲートによる併用療法
WO2015057250A1 (en) * 2013-10-18 2015-04-23 Psma Development Company, Llc Combination therapies with psma ligand conjugates
SG10201913977TA (en) * 2014-05-22 2020-03-30 Synthon Biopharmaceuticals Bv Site-specific conjugation of linker drugs to antibodies and resulting adcs
WO2016059377A1 (en) 2014-10-14 2016-04-21 Polytherics Limited Process for the conjugation of a peptide or protein with a reagent comprising a leaving group including a portion of peg
ES2960741T3 (es) * 2014-10-24 2024-03-06 Abzena Uk Ltd Conjugados y reactivos de conjugación
WO2019173324A1 (en) * 2018-03-06 2019-09-12 The Trustees Of The University Of Pennsylvania Prostate-specific membrane antigen cars and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2019527561A5 (OSRAM)
Tran et al. 99mTc-maEEE-ZHER2: 342, an Affibody molecule-based tracer for the detection of HER2 expression in malignant tumors
Wängler et al. Antibody− dendrimer conjugates: The number, not the size of the dendrimers, determines the immunoreactivity
Adumeau et al. A pretargeted approach for the multimodal PET/NIRF imaging of colorectal cancer
Hong et al. Positron emission tomography imaging of prostate cancer
Westerlund et al. Increasing the net negative charge by replacement of DOTA chelator with DOTAGA improves the biodistribution of radiolabeled second-generation synthetic affibody molecules
TWI795415B (zh) 新穎的抗人類CEACAM5抗體Fab片段
ES2800602T3 (es) Procedimientos y composiciones relacionados con los fragmentos de anticuerpos monocatenarios que se unen a la glucoproteína 72 asociada a tumor (TAG-72)
JP2017531028A5 (OSRAM)
JP2019511201A5 (OSRAM)
CA2646329A1 (en) Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting
TWI780082B (zh) 新穎抗人類MUC1抗體Fab片段
Maina et al. From bench to bed: New gastrin-releasing peptide receptor-directed radioligands and their use in prostate cancer
JP2020504607A5 (OSRAM)
ES2925224T3 (es) Anticuerpos monoclonales humanos contra EphA4 y su uso
EP4403226A3 (en) Anti-psma antibodies, uses thereof and conjugates thereof
Luo et al. Dual targeting of tissue factor and CD105 for preclinical PET imaging of pancreatic cancer
Spiegelberg et al. CD44v6‐Targeted Imaging of Head and Neck Squamous Cell Carcinoma: Antibody‐Based Approaches
CA3168866A1 (en) Anti-meflin antibody for use in treatment of cancer in subject having cancer, and pharmaceutical composition comprising the antibody
Uehara et al. 67/68Ga-labeling agent that liberates 67/68Ga-NOTA-methionine by lysosomal proteolysis of parental low molecular weight polypeptides to reduce renal radioactivity levels
Kim et al. Discovery of hapten-specific scFv from a phage display library and applications for HER2-positive tumor imaging
Altai et al. Radiolabeled probes targeting tyrosine-kinase receptors for personalized medicine
Niu et al. Molecular imaging of human epidermal growth factor receptor 2 (HER-2) expression
Altıparmak Güleç et al. Radiopharmaceuticals developed for 89Zr-Immuno-PET
WO2024097950A1 (en) Radionucleotide and near-infrared dye conjugated antibody for detection of gd2-positive cancer